Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.34 |
| ▸ | FPR3 | P25089 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841999 | 0.90 | OPRM1 (0.45) | FASNOPRM1SIGMAR1FPR3FPR2 | |
| SCHEMBL14720324 | 0.88 | SIGMAR1 (0.44) | FASNOPRM1SIGMAR1KCNH2 | |
| SCHEMBL15543324 | 0.83 | FASN (0.40) | FASNOPRM1SIGMAR1KCNH2 | |
| SCHEMBL15544449 | 0.82 | FASN (0.40) | FASNOPRM1SIGMAR1KCNH2 | |
| SCHEMBL15556185 | 0.81 | FASN (0.43) | FASNOPRM1SIGMAR1 | |
| SCHEMBL14842007 | 0.81 | FASN (0.40) | FASNOPRM1SIGMAR1FPR3FPR2 | |
| SCHEMBL15544705 | 0.80 | FASN (0.40) | FASNOPRM1SIGMAR1KCNH2 | |
| SCHEMBL15543650 | 0.80 | OPRM1 (0.42) | FASNOPRM1SIGMAR1KCNH2 | |
| SCHEMBL4534373 | 0.78 | FASN (0.51) | FASNFPR2 | |
| SCHEMBL14720191 | 0.77 | OPRM1 (0.46) | FASNOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |